



## NEWS RELEASE

# Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies

2025-11-13

National certification demonstrates enterprise-grade oversight of specialty pharmacy enablement programs

FORT WORTH, Texas--(BUSINESS WIRE)-- In a move that reinforces its leadership in enabling health system-owned specialty pharmacy growth, Omnicell, Inc. (Nasdaq:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced that its Specialty Pharmacy Services business has earned URAC Health Care Management Certification. This national certification recognizes that Omnicell holds itself to the highest industry standards in delivering quality clinical oversight, operational governance, and specialty pharmacy support. The certification is effective from October 1, 2025, through October 1, 2028.

URAC is the nation's leading independent accreditor of healthcare organizations, known for its rigorous standards and focus on continuous improvement. The Health Care Management Certification evaluates an organization's ability to deliver safe, effective, and coordinated services within a structured framework of clinical governance, risk management, and operational excellence.

"This certification reflects our deep commitment to enabling our health system customers to deliver compliant, high-performing specialty pharmacy services and 340B programs under their own brand," said Carmine DeNardo, RPh, vice president and general manager, Specialty Pharmacy Services at Omnicell. "It validates the rigor of our clinical protocols, the strength of our infrastructure, and that we meet industry standards in delivering quality services to our customers."

Unlike traditional outsourced models, which typically retain control over pharmacy operations, Omnicell's URAC-certified services are designed to enable health systems to launch and scale their own specialty pharmacy and 340B programs under their own pharmacy licenses, while allowing them to maintain full brand, clinical, and financial ownership.

“The URAC certification seal shows an organization’s commitment to high quality in health care in the areas of risk management, consumer protection and empowerment, operations and infrastructure, as well as performance management and improvement. We are proud to recognize Omnicell Specialty Pharmacy Services for its achievement in these areas,” said URAC President and CEO, Shawn Griffin, MD.

Omnicell’s Specialty Pharmacy Services supports leading health systems nationwide as they seek to improve access for complex patient populations, facilitate 340B program optimization, and implement strategies to improve operational performance.

Health system leaders exploring URAC-certified solutions for launching or expanding in-house specialty pharmacy can learn more at [omnicell.com/specialty-pharmacy](https://omnicell.com/specialty-pharmacy).

## About URAC

Founded in 1990 as a non-profit organization, URAC is the independent leader in promoting health care quality and patient safety through renowned accreditation programs. URAC develops its evidence-based standards in collaboration with a wide array of stakeholders and industry experts. The company’s portfolio of accreditation and certification programs spans the health care industry, addressing health equity, workplace mental health, health care management and operations, pharmacies, telehealth, health plans, medical practices and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.

## About Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit [omnicell.com](https://omnicell.com).

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

## Forward-Looking Statements

To the extent any statements contained in this press release deal with information that is not historical, these

statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s attainment and continuing retention of the URAC Health Care Management Certification, Version 3.0 and the expected outcomes and benefits of Omnicell’s Specialty Pharmacy Services offerings (and any implied financial impact). Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ii) changes to the 340B Program, (iii) risks presented by government regulations, legislative changes, fraud and anti-kickback statutes, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same; (iv) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, and (v) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at [www.sec.gov](http://www.sec.gov). Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

Betsy Martinelli  
Director, Corporate Marketing  
[betsy.martinelli@omnicell.com](mailto:betsy.martinelli@omnicell.com)

Source: Omnicell, Inc.